New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
07:15 EDTCUR, OSIR, BCLI, ATHX, NBS, PSTIRRY Publications to host a summit
8th Annual New York Stem Cell Summit '13 is being held in New York on February 19.
News For OSIR;PSTI;ATHX;CUR;NBS;BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
10:50 EDTBCLIBrainStorm management to meet with Maxim
Subscribe for More Information
08:27 EDTBCLIBrainStorm reports Q4 EPS (18c), one estimate (15c)
Subscribe for More Information
March 25, 2015
07:16 EDTPSTI, NBS, OSIR, BCLIPiper Jaffray and the Alliance for Regenerative Medicine co-host conference
3rd Annual Regenerative Medicine Investor Day is being held in New York on March 25 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
March 24, 2015
09:22 EDTPSTIOn The Fly: Pre-market Movers
Subscribe for More Information
05:29 EDTPSTIPluristem announces strategic objectives for PLX-R18 development
Subscribe for More Information
05:28 EDTPSTIPluristem announces key strategic objectives for PLX-R18 development
Subscribe for More Information
March 23, 2015
11:13 EDTOSIROsiris management to meet with Brean Capital
Subscribe for More Information
March 20, 2015
12:38 EDTOSIROsiris volatility at six-year low as shares near 20-month high
Subscribe for More Information
07:42 EDTNBSBioCentury to hold a conference
Subscribe for More Information
March 17, 2015
16:35 EDTOSIROsiris files to delay Form 10-K
Subscribe for More Information
11:15 EDTATHXAthersys management to meet with Maxim
Meeting to be held in New York on March 18 hosted by Maxim.
March 16, 2015
07:35 EDTCURNeuralstem reports FY14 EPS (26c), consensus (25c)
Subscribe for More Information
06:05 EDTNBSNeoStem announces PreSERVE AMI clinical trial one-year follow up results
NeoStem announced the presentation of updated efficacy and safety results from the one-year follow-up for its Phase 2 PreSERVE study and additional analyses of certain functional tests at ACC.15, the American College of Cardiology's 64th Annual Scientific Session and Expo, in San Diego, California. The one-year follow-up results are defined as all data accumulated until the last patient enrolled completed 12 month follow-up. Thus, the results actually represent data from patients with a median follow-up of 18 months. The PreSERVE study is NeoStem's clinical trial evaluating NBS10 which is being developed to treat damaged heart muscle following an acute myocardial infarction. One-year follow-up safety data collected thus far supports the trial's 6 month results presented at the American Heart Association's Scientific Sessions in November 2014. The ACC presentation contained updated safety and exploratory efficacy data and additional analyses conducted on left ventricular ejection fraction, or LVEF, data. Clinical Endpoint Committee adjudication of major adverse cardiac events, or MACE, was performed on the 6 month data reported previously and was not performed for new events. The next prescribed adjudication of MACE is currently planned at the end of patient follow-up. At 12-month follow-up, no meaningful safety or tolerance differences were observed between treatment and control groups. In this updated analysis, no additional deaths were reported in the treatment or control groups beyond those previously reported in the six month analysis. In addition, in post hoc subset analyses based on the number of cells patients received, serious adverse event frequency continues to show numerical improvement at all cell doses when compared to control.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use